A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Cited by (186)

Items 101–186 of 186

1. Allosteric Control of Structural Mimicry and Mutational Escape in the SARS-CoV-2 Spike Protein Complexes with the ACE2 Decoys and Miniprotein Inhibitors: A Network-Based Approach for Mutational Profiling of Binding and Signaling
   Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Journal of Chemical Information and Modeling
2. Low antispike antibody levels correlate with poor outcomes in COVID‐19 breakthrough hospitalizations
   Devang K. Sanghavi, Shivang Bhakta, Hani M. Wadei, Wendelyn Bosch, Jennifer B. Cowart, Rickey E. Carter, Sadia Z Shah, Benjamin D. Pollock, Matthew R. Neville, Sven Peter Oman et al. · 2022 · Journal of Internal Medicine
3. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
   Yuxin Chen, Liguo Zhu, Weijin Huang, Xin Tong, Hai Wu, Yue Tao, Bei Tong, Haibin Huang, Jiachen Chen, Xiang‐An Zhao et al. · 2021 · Emerging Microbes & Infections
4. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
   Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, Ronghua Shi, Tengchuan Jin · 2021 · Frontiers in Molecular Biosciences
5. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
   Fatima Amanat, Shirin Strohmeier, Philip S. Meade, Nicholas Dambrauskas, Barbara Mühlemann, Derek J. Smith, Vladimir I. Vigdorovich, D. Noah Sather, Lynda Coughlan, Florian Krammer · 2021 · PLoS Biology
6. Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers
   Felicia Trofin, Eduard Vasile Năstase, Luminița Smaranda Iancu, Daniela Constantinescu, Corina Maria Cianga, Cătălina Luncă, Ramona Gabriela Ursu, Petru Cianga, Olivia Dorneanu · 2022 · Pathogens
7. Functional SARS-CoV-2-sperific immune memory persists after mild COVID-19
   L. Rodda, Jason Netland, Laila Shehata, K. Pruner, P. Morawski, C. Thouvenel, K. Takehara, Julie Eggenberger, E. A. Hemann, H. Waterman et al. · 2020 · Research Square
8. Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
   Daniel N. Streblow, Alec J. Hirsch, J. Stanton, Anne D. Lewis, L. Colgin, A. Hessell, C. Kreklywich, Jessica L. Smith, William F. Sutton, David Chauvin et al. · 2023 · Nature Communications
9. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
   L. Adams, Laura A. VanBlargan, Zhuo-Ming Liu, P. Gilchuk, Hai-Yan Zhao, Rita E. Chen, S. Raju, Zhen-Lu Chong, Bradley M. Whitener, S. Shrihari et al. · 2023 · Cell Reports Medicine
10. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
    Caroline Hirsch, Sarah J Valk, Vanessa Piechotta, Khai Li Chai, Lise J Estcourt, Ina Monsef, Susanne Salomon, Eve Tomlinson, Maria Popp, Erica M. Wood et al. · 2021 · Cochrane Database of Systematic Reviews
11. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
    Wen Su, Sin Fun Sia, Aaron J. Schmitz, Traci L. Bricker, Tyler N. Starr, Allison J. Greaney, Jackson S. Turner, Bassem M. Mohammed, Zhuoming Liu, Ka Tim Choy et al. · 2021 · mBio
12. Warmer Ambient Air Temperatures Reduce Nasal Turbinate and Brain Infection, But Increase Lung Inflammation in the K18-hACE2 Mouse Model of COVID-19
    Troy D. Dumenil, Thuy T. Le, Daniel J. Rawle, Kexin Yan, Bing Tang, Wilson Nguyen, Cameron Bishop, Andreas Suhrbier · 2022 · The Science of The Total Environment
13. Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies
    Magdalena M. Zak, Aryeh Stock, D. Stadlbauer, Wei Zhang, K. Cummings, William Marsiglia, Arsen Zargarov, Fatima Amanat, M. Tamayo, C. Cordon-Cardo et al. · 2021 · Heliyon
14. Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI
    Edward D. B. Lopatto, Jesús M. Santiago-Borges, Denise A. Sanick, Sameer Kumar Malladi, Philippe N. Azimzadeh, Morgan R. Timm, Isabella F. Fox, Aaron J. Schmitz, Jackson S. Turner, Shaza M. Sayed Ahmed et al. · 2025 · Science Advances
15. De novo design of epitope-specific antibodies via a structure-driven computational workflow
    Fandi Wu, Yu Shan Zhao, Jiaxiang Wu, Biaobin Jiang, Bing He, Long-Kai Huang, Chenchen Qin, Yang Xiao, Fan Yang, Rubo Wang et al. · 2025 · Nature Communications
16. Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
    Mahali S. Morgan, Kexin Yan, Thuy T. Le, Ryan A. Johnston, Alberto Anastacio Amarilla, David Alexander Muller, Christopher L. D. McMillan, Naphak Modhiran, Daniel Watterson, James R. Potter et al. · 2022 · Viruses
17. Fast and accurate modeling and design of antibody-antigen complex using tFold
    Fandi Wu, Yu Shan Zhao, Jiaxiang Wu, Biaobin Jiang, Bing He, Long-Kai Huang, Chenchen Qin, Fan Yang, Ningqiao Huang, Yang Xiao et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
18. CD62L expression marks a functionally distinct subset of memory B cells
    Christopher H. Hanson, Brittany Henry, Pradhnesh Andhare, Frank J. Lin, Haley Pak, Jackson S. Turner, Lucas J. Adams, Tom Liu, Daved H. Fremont, Ali H. Ellebedy et al. · 2023 · Cell Reports
19. Relevance of BET Family Proteins in SARS-CoV-2 Infection
    Nieves Lara-Ureña, Mario García‐Domínguez · 2021 · Biomolecules
20. mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes
    Ofer Zimmerman, Alexa Michelle Altman Doss, Paulina Kapłonek, Chieh-Yu Liang, Laura A. VanBlargan, Rita E. Chen, Jennifer Marie Monroy, H. James Wedner, Anthony Kulczycki, Tarisa L. Mantia et al. · 2022 · Cell Reports Medicine
21. Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31
    Francesca Levi‐Schaffer, Ario de Marco · 2021 · British Journal of Pharmacology
22. Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization
    Sameer Kumar Malladi, Deepika Jaiswal, Baoling Ying, Wafaa B. Alsoussi, Tamarand L. Darling, Bernadeta Dadonaite, Alesandro Civljak, Stephen C. Horvath, Julian Q. Zhou, Wooseob Kim et al. · 2025 · Science Immunology
23. Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity
    Ofer Zimmerman, Alexa Michelle Altman Doss, Baoling Ying, Chieh-Yu Liang, Samantha Mackin, Hannah G. Davis-Adams, Lucas J. Adams, Laura A. VanBlargan, Rita E. Chen, Suzanne M. Scheaffer et al. · 2024 · JCI Insight
24. Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19
    Natalie M. Kirk, Yu-Ying Liang, H. Ly · 2024 · Virulence
25. Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
    Pooya Farhangnia, Shiva Dehrouyeh, Amir Reza Safdarian, Soheila Vasheghani Farahani, Melika Gorgani, Nima Rezaei, Mahzad Akbarpour, Ali‐Akbar Delbandi · 2022 · International Immunopharmacology
26. Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates
    Paule Hermet, Benoît Delache, Cécile Hérate, Esther Wolf, Gaily Kivi, Erkki Juronen, Karl Mumm, Eva Žusinaite, Denis E. Kainov, Eve Sankovski et al. · 2023 · PLoS Pathogens
27. Targeting the Receptor-Binding Motif of SARS-CoV-2 with D-Peptides Mimicking the ACE2 Binding Helix: Lessons for Inhibiting Omicron and Future Variants of Concern
    Pedro Alberto Valiente, Satra Nim, JinAh Lee, Seungtaek Kim, Philip M. Kim · 2022 · Journal of Chemical Information and Modeling
28. PI3Kγ in B cells promotes antibody responses and generation of antibody-secreting cells
    Stephen M. Lanahan, Lucas Yang, Kate M. Jones, Zhihong Qi, Emylette Cruz Cabrera, Lauren Y. Cominsky, Anjali Ramaswamy, Anis Barmada, Gisela Gabernet, Dinesh Babu Uthaya Kumar et al. · 2024 · Nature Immunology
29. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity
    Alona Kuzmina, Seraj Wattad, Stanislav Engel, Elli Rosenberg, Ran Taube · 2022 · Viruses
30. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
    Guidenn Sulbarán, Pauline Maisonnasse, Axelle Amen, Grégory Effantin, Delphine Guilligay, Nathalie Dereuddre‐Bosquet, Judith A. Burger, Meliawati Poniman, Marloes Grobben, Marlyse Buisson et al. · 2022 · Cell Reports Medicine
31. Repeat modules and N-linked glycans define structure and antigenicity of a critical enterotoxigenic E. coli adhesin
    Zachary T. Berndsen, Marjahan Akhtar, Mahima Thapa, Tim J. Vickers, Aaron J. Schmitz, Jonathan L. Torres, Sabyasachi Baboo, Pardeep Kumar, Nazia Khatoon, Alaullah Sheikh et al. · 2024 · PLoS Pathogens
32. Identification of a seasonal influenza vaccine–induced broadly protective neuraminidase antibody
    Anders Madsen, Nisreen M.A. Okba, Tossapol Pholcharee, Hanover C. Matz, Huibin Lv, Maria Ibanez Trullen, Julian Q. Zhou, Jackson S. Turner, Aaron J. Schmitz, Fangjie Han et al. · 2025 · The Journal of Experimental Medicine
33. High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium
    Bas Calcoen, Nico Callewaert, Aline Vandenbulcke, Winnie Kerstens, Maya Imbrechts, Thomas Vercruysse, Kai Dallmeier, Johan Van Weyenbergh, Piet Maes, Xavier Bossuyt et al. · 2022 · Viruses
34. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients
    Frank J. Lin, Alexa Michelle Altman Doss, Hannah G. Davis-Adams, Lucas J. Adams, Christopher H. Hanson, Laura A. VanBlargan, Chieh-Yu Liang, Rita E. Chen, Jennifer Marie Monroy, H. James Wedner et al. · 2022 · Frontiers in Immunology
35. Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
    Puja Jaishwal, Kisalay Jha, Satarudra Prakash Singh · 2024 · International Journal of Biological Macromolecules
36. Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies
    D. Beshnova, Yan Fang, Mingjian Du, Yehui Sun, Feng-He Du, Jianfeng Ye, Zhi-Jian J. Chen, Bo Li · 2022 · Computational and Structural Biotechnology Journal
37. Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology
    Sundararaj Stanleyraj Jeremiah, Kei Miyakawa, Akihide Ryo · 2022 · Journal of Molecular Cell Biology
38. Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein
    Devivasha Bordoloi, Ziyang Xu, Michelle Ho, Mansi Purwar, Pratik Sanjivkumar Bhojnagarwala, Joel A. Cassel, Leila B. Giron, Susanne N. Walker, Abhijeet J. Kulkarni, Edgar Tello‐Ruiz et al. · 2021 · ACS Pharmacology & Translational Science
39. mRNA—From COVID-19 Treatment to Cancer Immunotherapy
    W. Kŕause · 2023 · Biomedicines
40. Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity
    Alona Kuzmina, Dina Korovin, Ido Cohen-Lass, Nofar Atari, Aner Ottolenghi, Pan Hu, Michal Mandelboim, Benyamin Rosental, Elli Rosenberg, Felipe Diaz‐Griffero et al. · 2023 · Heliyon
41. Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population
    Carlos A. Sariol, Crisanta Serrano-Collazo, Edwin J. Ortiz, Petraleigh Pantoja, Lorna A. Cruz, Teresa Arana, Dianne Atehortua, Christina Pabon-Carrero, Ana Margarita Espino · 2021 · Viruses
42. Protoporphyrin IX and verteporfin prevent SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2
    Chenjian Gu, Yang Wu, Huimin Guo, Yuanfei Zhu, Wei Xu, Yuyan Wang, Yu Zhou, Zhiping Sun, Xia Cai, Yutang Li et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
43. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
    Li Fu, Dean Gilham, Stephanie C. Stotz, Christopher D. Sarsons, Brooke D. Rakai, Laura M. Tsujikawa, Sylwia Wasiak, Jan O. Johansson, Michael Sweeney, Norman C.W. Wong et al. · 2023 · International Immunopharmacology
44. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration
    Germain Simon, Julien Favresse, Constant Gillot, Mélanie Closset, Émilie Catry, Jean‐Michel Dogné, Jonathan Douxfils, Grégoire Wieërs, Jean‐Louis Bayart · 2023 · Clinical Chemistry and Laboratory Medicine (CCLM)
45. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels
    Qiru Zeng, Avan Antia, Luis Alberto Casorla-Perez, Maritza Puray‐Chavez, Sebla B. Kutluay, Matthew A. Ciorba, Siyuan Ding · 2024 · mBio
46. Pre-clinical models to define correlates of protection for SARS-CoV-2
    Caolann Brady, Tom Tipton, Stéphanie Longet, Miles W. Carroll · 2023 · Frontiers in Immunology
47. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
    Piccoli, Luca, Park, Young-Jun, Tortorici, M. Alejandra, Czudnochowski, Nadine, Walls, Alexandra C., Beltramello, Martina, Silacci-Fregni, Chiara, Pinto, Dora, Rosen, Laura E., Bowen, John E. et al. · 2020 · Cell
48. A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection
    Ahmed O. Hassan, Natasha M. Kafai, I. Dmitriev, J. Fox, Brittany K. Smith, Ian B. Harvey, Rita E. Chen, Emma S. Winkler, Alex W. Wessel, J. Case et al. · 2020 · bioRxiv
49. P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants
    A. Kuzmina, N. Atari, A. Ottolenghi, D. Korovin, Ido Cohen lass, B. Rosental, Elli Rosenberg, M. Mandelboim, R. Taube · 2022 · bioRxiv
50. Prototype mRNA vaccines imprint broadly neutralizing human serum antibodies after Omicron variant-matched boosting
    Chieh-Yu Liang, Saravanan Raju, Zhuoming Liu, Yuhao Li, Guha Asthagiri Arunkumar, James Brett Case, Seth J. Zost, Cory M. Acreman, Déborah Carolina Carvalho dos Anjos, Jason S. McLellan et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
51. A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination
    Fabien Abdul, Pascale Ribaux, Aurélie Caillon, Astrid Malézieux-Picard, Virginie Prendki, Nathalie Vernaz, Nikolay Zhukovsky, Flavien Delhaes, Karl‐Heinz Krause, Olivier Preynat‐Seauve · 2022 · Viruses
52. Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI
    Edward D. B. Lopatto, Jesús M. Santiago-Borges, Denise A. Sanick, Sameer Kumar Malladi, Philippe N. Azimzadeh, Morgan R. Timm, Isabella F. Fox, Aaron J. Schmitz, Jackson S. Turner, Shaza Sayed Ahmed et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
53. Salivary immune responses after COVID-19 vaccination
    Kenny Nguyen, Boris Relja, Monica Epperson, Sohee Park, Natalie J. Thornburg, Verónica Costantini, Jan Vinjé · 2024 · PLoS ONE
54. Humanized mice enable in vivo evaluation of engineered plasma cell biology and therapeutic function
    Tyler F. Hill, Anna E Helmers, Rene Yu-Hong Cheng, Swati Singh, Leah J. Homad, Parnal Narvekar, Gregory D. Asher, Nathan D. Camp, Emmaline R. Suchland, Andee R. Ott et al. · 2026 · Molecular Therapy Advances
55. 19. Einsatz gentechnologischer Methoden in der Impfstoffentwicklung gegen das SARS-CoV-2-Virus
    Martin Körte · 2021 · Nomos Verlagsgesellschaft mbH & Co. KG eBooks
56. Microfluidics-enabled fluorescence-activated cell sorting of single pathogen-specific antibody secreting cells for the rapid discovery of monoclonal antibodies
    Katrin Fischer, Aleksei Lulla, Tsz Y. So, Pehuén Pereyra-Gerber, Matthew I. J. Raybould, Timo N. Kohler, Tomasz S. Kamiński, Juan Carlos Yam‐Puc, Robert Hughes, Florian Leiss-Maier et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
57. Intranasal vaccination of Syrian Hamsters with ChAd-SARS-CoV-2-S disrupts airborne transmission cycles of SARS-CoV-2
    Adrianus C. M. Boon, Tamarand L. Darling, Houda Harastani, Astha Joshi, Traci L. Bricker, Kuljeet Seehra, Ahmed O. Hassan, Michael Diamond · 2023 · Research Square
58. Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein
    Sameer Kumar Malladi, Deepika Jaiswal, Baoling Ying, Wafaa B. Alsoussi, Tamarand L. Darling, Bernadeta Dadonaite, Alesandro Civljak, Stephen C. Horvath, Julian Q. Zhou, Wooseob Kim et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
59. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina
    R. J. Eliçabe, Matías Nicolás Distel, B. Jofré, Marianela Leporati, J. E. Silva, J. Arias, C. Gorlino, S. Funes, Marisol Velazquez, Patricia Vitale et al. · 2022 · Vaccine
60. SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study
    Ketlyn Oliveira, Ana Almeida, Carina Silva, Miguel Brito, Edna Ribeiro · 2024 · Infectious Disease Reports
61. Human enterotoxigenic Escherichia coli (ETEC) infections elicit antibodies that broadly neutralize mucinases of pathogenic Escherichia coli and Shigella
    David P. Buckley, Marjahan Akhtar, Mahima Thapa, Aaron J. Schmitz, Jackson S. Turner, Tim J. Vickers, Nazia Khatoon, M. Hasanul Kaisar, Jonathan Coggin, Debayan Ganguli et al. · 2026 · Proceedings of the National Academy of Sciences
62. Monoclonal neutralizing antibodies against SARS-COV-2 S protein
    Lin-Dong Cheng · 2024 · American Journal of Translational Research
63. Structure-based Design of a Specific, Homogeneous Luminescence Enzyme Reporter Assay for SARS-CoV-2
    Frederic A. Fellouse, Shane Miersch, Chao Chen, S. Michnick · 2021 · Journal of Molecular Biology
64. A comparative study between COVID-19 vaccine (Pfizer and Sinopharm) and their relationship to some cytokines
    Baidaa Shaheed Tuama, Abeer Fauzi Al–Rubaye, Amal Merza · 2023 · Bionatura
65. Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
    Fatima Amanat, Shirin Strohmeier, Philip S. Meade, Nicholas Dambrauskas, Barbara Mühlemann, Derek J. Smith, Vladimir I. Vigdorovich, D. Noah Sather, Lynda Coughlan, Florian Krammer · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
66. Calpain-2 mediates SARS-CoV-2 entry and represents a therapeutic target
    Qiru Zeng, Avan Antia, Maritza Puray‐Chavez, Sebla B. Kutluay, Siyuan Ding · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
67. De Novo Design of Miniprotein Inhibitors of Bacterial Adhesins
    Adam M. Chazin-Gray, Tuscan Rock Thompson, Edward D. B. Lopatto, Pearl Magala, Patrick W. Erickson, Andrew C. Hunt, Anna Manchenko, Pavel Aprikian, Veronika L Tchesnokova, Irina Basova et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
68. Vacunas contra COVID19. Una carrera contra el tiempo
    Xavier Sáez‐Llorens · 2020 · Revista médica de Panamá
69. AS739, AT693 and AU734 antibodies recognize the spike S protein from SARS-CoV-2 by ELISA
    Nina Payot, Alexandre Pierre Vaudano, Khatiba Khatibi, Anthony Nemeth, Ezgi Gozlugol, Nylsa Chammartin, Célia Lazzarotto, Julien Ollivier, Sara Da Fonte, Emma Jaques et al. · 2021 · Antibody Reports
70. AS739, AT693, AU197 and AU734 antibodies label the spike S protein from SARS-CoV-2 by western blot
    Célia Lazzarotto, Marie N. Schmid, Julien Ollivier, Alexandre Pierre Vaudano, Sara Da Fonte, Nina Payot, Anthony Nemeth, Clément Bindschaedler, Khatiba Khatibi, Nylsa Chammartin et al. · 2021 · Antibody Reports
71. AS739, AT693 and AU734 antibodies label the spike S protein from SARS-CoV-2 by immunofluorescence
    Cyril Guilhen, Nylsa Chammartin, Célia Lazzarotto, Sara Da Fonte, Anthony Nemeth, Clément Bindschaedler, Zacharie El Matribi, Serkan Berkcan, Ezia Oppliger, Daniel Gil et al. · 2021 · Antibody Reports
72. AQ806, AS739, AT693, AU197 and AU734 antibodies recognize the spike S protein from SARS-CoV-2 by flow cytometry
    Margaux Gosetto, Daniel Gil, Clément Poncet, Maxime Volery, Sara Da Fonte, Emma Jaques, Zacharie El Matribi, Serkan Berkcan, Nina Payot, Alexandre Pierre Vaudano et al. · 2021 · Antibody Reports
73. Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)
    Ciarán Richardson, Sarah Gildea, Stephen Harkin, Annie Gallagher, Eimear Conroy, Lorraine McClafferty, Eibhlin McCole, El Ouard Benchikh, Cherith N. Reid, Marshall Dunlop et al. · 2021 · medRxiv
74. Directed Evolution of Antibodies Against Complex Targets
    Alec A. Desai · 2021 · Deep Blue (University of Michigan)
75. Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan
    Ahmed Donia, Muhammad Nawaz, Muhammad Furqan Shahid, Ramla Shahid, A. Javed, Tahir Yaqub, Habib Bokhari · 2024 · Acta Medica Bulgarica
76. Antibody Responses to SARS-Cov-2 among Health Care Workers of a Tertiary Hospital in North-Eastern, Tanzania
    Pendo Mussa Ibrahim, Felix Anthony, Happiness Mshana, Kevin Rwegoshola, Hadija Hamis Semvua, Jaffu Othniel Chilongola · 2024 · medRxiv
77. ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2
    Jenna K. Dick, Dustin M. Hicks, Venkatramana Divana Krishna, Jules A. Sangala, Benjamin T. Zandstra, Carly Baehr, J. Sjef Verbeek, Mark Steven Cragg, Maxim C.‐J. Cheeran, Marco Pravetoni et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
78. Evaluation of a surrogate virus neutralization assay for detecting neutralizing antibodies against SARS-CoV-2 in an African population
    Lilian Nkinda, Victoria Shayo, Salim S. Masoud, Godfrey Barabona, I. Ngare, Ponsian P Kunambi, Emmanuel Nkuwi, D. Kamori, F. Msafiri, E. Osati et al. · 2024 · Biology Methods and Protocols
79. A Versatile High‐Throughput Single‐Cell Screening Platform for Profiling Antigen‐Specific Long‐Lived B Cells in Blood and Bone Marrow
    Tian Zhao, Yuqing Lei, Chang Liu, Dong Zhang, Kaiyi Li, Sisi Shan, Chenyu Li, Zimeng Wei, Yuhan Yang, Ting Zhang et al. · 2025 · Advanced Science
80. Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primates
    Тухватулин Амир Ильдарович, Ilya V. Gordeychuk, Alina Sh. Dzharullaeva, Inna V. Dolzhikova, Баюрова Екатерина Олеговна, Fatima M. Izhaeva, Ковыршина Анна Витальевна, Житкевич Алла Сергеевна, Darya Avdoshina, Stanislav A. Gulyaev et al. · 2025 · Frontiers in Immunology
81. CD8 + Tissue‐Resident Memory T Cells in Health and Disease
    Yu-Han Ai, Ting‐Ting Xu, Sen Lin, Meng‐Yu Xiao, Yun-Xia Lin, H Y Ma, Liu Y, Yao‐Jie Wang, Lu‐Ning Yin, Mei Huang et al. · 2026 · MedComm
82. CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells
    Samuel Ameh, Derek J. Theisen, Mahima Thapa, Jackson S. Turner, Abhinav Rangarajan, Christopher A. Nelson, Aaron J. Schmitz, Yuang Song, Ruan F.V. Medrano, Cora D. Arthur et al. · 2026 · Cancer Immunology Research
83. Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants
    Naveenchandra Suryadevara, Seth J. Zost, John M. Powers, Bernadeta Dadonaite, Pavlo Gilchuk, Elad Binshtein, Suzanne M. Scheaffer, Sarah R. Leist, Luke Myers, Silvia Ravera et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
84. ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2.
    Jenna K. Dick, V. Krishna, D. Hicks, Jules A. Sangala, Robert J. Oldham, Benjamin T. Zandstra, C. Baehr, J. Verbeek, M. Cragg, M. Pravetoni et al. · 2026 · Journal of Immunology
85. Dataset for: Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI
    Edward D. B. Lopatto · 2025 · Zenodo (CERN European Organization for Nuclear Research)
86. BLI dataset for: Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI
    Edward D. B. Lopatto · 2024 · Zenodo (CERN European Organization for Nuclear Research)